Show simple item record

dc.contributor.authorGilbert, Fiona
dc.contributor.authorHickman, Sarah
dc.contributor.authorBaxter, Gabrielle
dc.contributor.authorAllajbeu, Iris
dc.contributor.authorJames, J
dc.contributor.authorCaraco, C
dc.contributor.authorVinnicombe, S
dc.date.accessioned2022-03-29T23:30:46Z
dc.date.available2022-03-29T23:30:46Z
dc.date.issued2021-10
dc.identifier.issn0009-9260
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/335492
dc.description.abstractIn the UK, women between 50-70 years are invited for 3-yearly mammography screening irrespective of their likelihood of developing breast cancer. The only risk adaption is for women with >30% lifetime risk who are offered annual magnetic resonance imaging (MRI) and mammography, and annual mammography for some moderate-risk women. Using questionnaires, breast density, and polygenic risk scores, it is possible to stratify the population into the lowest 20% risk, who will develop <4% of cancers and the top 4%, who will develop 18% of cancers. Mammography is a good screening test but has low sensitivity of 60% in the 9% of women with the highest category of breast density (BIRADS D) who have a 2.5- to fourfold breast cancer risk. There is evidence that adding ultrasound to the screening mammogram can increase the cancer detection rate and reduce advanced stage interval and next round cancers. Similarly, alternative tests such as contrast-enhanced mammography (CESM) or abbreviated MRI (ABB-MRI) are much more effective in detecting cancer in women with dense breasts. Scintimammography has been shown to be a viable alternative for dense breasts or for follow-up in those with a personal history of breast cancer and scarring as result of treatment. For supplemental screening to be worthwhile in these women, new technologies need to reduce the number of stage II cancers and be cost effective when tested in large scale trials. This article reviews the evidence for supplemental imaging and examines whether a risk-stratified approach is feasible.
dc.format.mediumPrint-Electronic
dc.publisherElsevier BV
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectBreast
dc.subjectBreast Neoplasms
dc.subjectDiagnostic Imaging
dc.subjectEarly Detection of Cancer
dc.subjectFemale
dc.subjectHumans
dc.subjectRisk
dc.titleOpportunities in cancer imaging: risk-adapted breast imaging in screening.
dc.typeArticle
dc.publisher.departmentDepartment of Radiology
dc.date.updated2022-03-29T09:16:02Z
prism.endingPage773
prism.issueIdentifier10
prism.publicationDate2021
prism.publicationNameClin Radiol
prism.startingPage763
prism.volume76
dc.identifier.doi10.17863/CAM.82923
dcterms.dateAccepted2021-02-19
rioxxterms.versionofrecord10.1016/j.crad.2021.02.013
rioxxterms.versionAM
dc.contributor.orcidGilbert, Fiona [0000-0002-0124-9962]
dc.contributor.orcidHickman, Sarah [0000-0002-4637-7300]
dc.contributor.orcidBaxter, Gabrielle [0000-0002-8242-1559]
dc.contributor.orcidAllajbeu, Iris [0000-0002-6419-2422]
dc.identifier.eissn1365-229X
rioxxterms.typeJournal Article/Review
pubs.funder-project-idCancer Research Uk (None)
pubs.funder-project-idCancer Research UK (A26884)
pubs.funder-project-idNational Institute for Health Research (NIHRDH-IS-BRC-1215-20014)
cam.orpheus.success2022-03-29 - Embargo set during processing via Fast-track
cam.depositDate2022-03-29
pubs.licence-identifierapollo-deposit-licence-2-1
pubs.licence-display-nameApollo Repository Deposit Licence Agreement
rioxxterms.freetoread.startdate2022-10-31


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's licence is described as Attribution-NonCommercial-NoDerivatives 4.0 International